After ALS drug failure, Amylyx aims at GLP-1 through acquisition

Amylyx Pharmaceuticals Inc. is breaking into metabolic disease work with the purchase of a clinical-stage drug from the California company that filed for bankruptcy earlier this year.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks